MYSTIC, Conn. and DUBLIN, July 7, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the successful completion of the remaining non-clinical studies for the Company's planned new drug application (NDA) for AMR101 for the treatment of patients with very high triglycerides (=500 mg/dl) and confirmed an expected Q3 2011 NDA submission.
